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1. INTRODUCTION 
 
1.1.  Historical overview of pediatric liver transplantation 
 
Liver transplantation (LT) has become a routine treatment for terminal liver 
failure of both acute and chronic liver disease in children. In 1983, the National 
Institute of Health Consensus Development Conference declared that liver 
transplantation was an effective therapy for end-stage liver disease both in 
adults and children [1]. This declaration was made 20 years after Dr. Thomas 
Starzl performed the first human liver transplant in 1963 in Denver, Colorado, 
USA  [2]. Improvement of survival in the first decade of pediatric LT (pLT) was 
hampered by the lack of effective immunosuppressants which led to a high 
incidence of acute and chronic rejection. Only after the introduction of 
cyclosporine (CSA) as an immunosuppressant by Sir Roy Calne in 1977, 
patient outcome after liver transplantation in children improved [3] and has 
reached a present long-term patient survival rate of more than 90% in 
experienced pediatric transplant centers [2]. Hence, what started with the 
pioneering efforts of T.E. Starzl 50 years ago has now become a routinely 
successful clinical procedure. This achievement was made through refining the 
surgical techniques, immunosuppression, intensive care, better prevention and 
control of infection, and earlier re-transplantation when the first graft failed [4, 5]. 
Over the years, multiple indications for pediatric liver transplants have emerged 
and will now be discussed in detail before taking a deeper look into further 
developments in pediatric liver transplantation.  
  
1.2.  Indications for liver transplantation in children 
 
1.2.1.  Cholestatic disorders  
 
Biliary Atresia (BA) is the most common indication for chronic liver failure in 
infancy and childhood and accounts for at least 50% of all liver transplants in 
children. It is a disease of the infant which causes severe damage and 
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obliteration of the bile duct system leading to profound cholestasis and 
progressive biliary cirrhosis [6, 7]. For the majority of children, a surgical repair 
(Kasai procedure) is only temporary. Half of these patients undergo LT within 
the first 1-2 years of life and 80% during childhood [8]. The fact that BA is the 
most frequent indication for LT in childhood, explains the very young average 
age at transplantation. This favors complications such as vascular or biliary 
strictures due to the very small anatomic structures in technically modified grafts 
as well as a high likelihood of adverse reactions due to immunosuppression. 
Alagille Syndrome is a rare autosomal dominant disorder caused by a variety of 
mutations in the JAG1 gene, which is a ligand in the Notch signaling pathway 
that controls the development of many organs [9]. Therefore, clinical features 
vary, but are dominated by liver (chronic cholestasis due to the paucity of 
interlobular bile ducts) and heart disease (vascular and cardiac anomalies). 
Further organ systems may be affected. Approximately 50% of patients who 
present in infancy with clinically evident and progressive liver disease will not 
survive into adulthood without LT [10]. Progressive Familial Intrahepatic 
Cholestasis (PFIC) is a group of autosomal-recessive inherited disorders of 
transport proteins. In patients affected by high-impact mutations symptoms of 
liver disease including cholestasis, pruritus and jaundice are seen in the first 
year of life. Ursodeoxycholic acid therapy should be initiated in all patients to 
activate compensatory mechanisms. However, in many PFIC patients with high 
impact proteins, LT has to be considered before reaching adulthood due to 
possible fibrosis or end-stage liver disease [11].  
 
1.2.2.  Metabolic disorders 
 
Wilson's Disease (WD) is a rare autosomal-recessive disease characterized by 
the deposition of copper in the brain, liver; cornea, and other organs due to 
impairment of the biliary route for excretion of dietary copper [12]. The overload 
of copper inevitably leads to progressive liver and neurological dysfunction. The 
standard treatment for WD is chelation and zinc. Pediatric liver transplantation 
is reserved for those patients presenting with acute liver failure or rarely with 
7 
 
chronic failure despite medical therapy [13].  
 
1.2.3.  Other indications 
 
Neonatal Hemochromatosis (NH, meanwhile Gestational Alloimmune Liver 
Disease, GALD) is a rare disease in which liver injury of alloimmune origin and 
fetal onset is associated with massive extrahepatic iron deposition and liver 
failure. It presents with signs of terminal liver failure around birth [14]. If the 
current treatment including exchange transfusions and IV immunoglobulin fails, 
LT can be lifesaving. Autoimmune Hepatitis (AIH) is diagnosed based on the 
presence of either anti-smooth muscle antibody (SMA) (type1) or anti-liver-
kidney microsomal (LKM) antibody (type2). Children with type 2 AIH often tend 
to be younger, male and more likely to present with acute liver failure. Of 
children with AIH, 10-20% will eventually need LT [15]. Acute liver failure (ALF) 
in children is defined as a rapid onset hepatic necrosis presenting with or 
without hepatic encephalopathy and coagulopathy with INR > 2 within 8 weeks 
of the onset of clinical liver disease. The etiology of 49% of pediatric ALF cases 
is categorized as “indeterminate”, followed by acetaminophen toxicity (14%), 
metabolic disease (10%), drug toxicity (5%), and others (11%) [16]. Because 
there is a chance of spontaneous recovery, 54% of ALF patients will not require 
LT, approximately 32% of ALF patients require LT and 14% die without LT [16]. 
Hepatoblastoma is the most common pediatric liver tumor that is amenable to 
LT.  Protocol treatment includes chemotherapy to reduce the tumor volume and 
if a surgical removal is still not possible and no unresectable metastases are 
found, LT may be offered [17]. The number of transplants due to hepatic tumors 
is increasing posing a special challenge considering the immunosuppressive 
therapy due to risk of disease recurrence. 
 
1.3.  Surgical transplant techniques 
 
The technique of orthotopic liver transplantation (OLT) has developed since the 
original technique described by T.E. Starzl. Full-size grafts are still considered 
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anatomically ideal since the anatomy is preserved, resulting in better outcomes 
and less surgical complications. However, the shortage of size-matched donor 
organs for small children stimulated the development of technical innovations to 
increase the donor pool [2]. Reduced size liver transplantation describes a 
technique of ex situ liver reduction where a liver is cut to the volume of 
segments needed and the rest discarded. Usually, either the left lateral segment 
(segments 2-3) or the full left lobe (segments 2-4) is retained. However, liver 
reduction has been criticized and has become obsolete due to the loss of 
potentially transplantable segments. Split-liver transplantation (SLT) also 
increases the donor pool as it usually simultaneously offers a donor organ for a 
small (segments 2 and 3, in many cases pediatric) and an adult recipient. 
Technically, it is a complex procedure that can be performed either in the ex situ 
or in situ split technique [18-20]. Unfortunately, the wider application of the split 
technique is still hindered by the lack of experience and missing universal 
acceptance in transplant centers.  Living related liver transplantation (LRLT) is a 
further option to increase the donor pool, particularly for infant patients or 
younger children. Provided that the donor is suitable by anatomic means, 
contraindications are excluded and  perioperative risks are minimized, the donor 
will most commonly donate the left lateral segment (segments 2-3) or rarely the 
right (segments 5-8) or left lobe (segments 2-4) of the liver [21]. The surgical 
risk for the donor is relatively low when the left-lateral segment is transplanted. 
In addition to alleviate the organ shortage, this option has the advantage that 
the recipient can be prepared in order to perform the LT in an elective setting. 
To summarize, the types of grafts used in children include: full-size donor organ 
following post-mortem donation (51%), reduced liver (21%), living donor liver 
(20%), and split liver (8%) [22]. It is important to be informed about the type of 
graft received in order to anticipate technique-specific complications. 
 
1.4.  Complications associated with pediatric liver transplantation 
 
Presently, according to data from European centers collected in the European 
Liver Transplant Registry (ELTR), graft loss in the first year after pLT occurs in 
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28% of cases and mortality is 15-17%. Early recognition and correction of post-
transplant complications improve graft and patient survival. Complications can 
occur both in the early (during the initial post-transplant hospitalization) or late 
course after LT (generally after patients have been discharged home, weeks or 
months to years after transplantation). The majority of complications and deaths 
occur within the first three months [23, 24]. Primary non-function (PNF) of the 
graft, with an incidence in pediatrics of < 5% (0-16%) [25], manifests 12-48h 
after transplantation and includes rising INR (>3), AST or ALT (>5000IU/L), and 
bilirubin [22]. It results in graft loss, with only one third of children with PNF 
surviving [26]. Causes include impaired quality of the donor organ, difficulties in 
organ preservation and retrieval, and technical or immunological complications 
in the recipient [27]. The only effective treatment is emergent re-transplantation.  
 
1.4.1.  Vascular and biliary complications 
 
Vascular and bile duct anastomoses of the liver graft can differ in children 
compared to adults. Arterial reconstruction is mostly performed by end-to-end 
arterial anastomosis. Due to the small diameter of the vessels in children, 
anastomoses are difficult to perform and may result in vascular thrombosis or 
stenosis more frequently. Hepatic artery thrombosis (HAT), as the most feared 
surgical complication, has a reported incidence of 3% in adults and 7-8% in 
children [28]. It may present insidiously, with fever, cholangitis or biliary leaks, 
strictures or abscesses. Early recognition and immediate surgical 
revascularization may salvage the graft. Hepatic artery stenosis occurs in 5-
10% of the cases and can be successfully managed with angioplasty or stenting 
by an experienced interventional radiologist. Portal vein thrombosis (PVT), rare 
in adults, occurs in up to 33% of pediatric liver transplant recipients [29]. Early 
PVT presents with graft dysfunction or gastrointestinal bleeding. Screening with 
abdominal Doppler ultrasound during the first days after LT is routine to detect 
vascular thrombosis at a time when intervention is still possible. Following 
heparinization for the first seven days post pLT, prophylaxis against vascular 
thrombosis with oral aspirin is standard for the first 2-3 months after LT in the 
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protocol used at the local Tübingen center as well as in many other centers. 
Intra-abdominal bleeding, particularly from the cut surface of the liver (in a 
reduced or split graft), may require relaparotomy to stop the hemorrhage. This 
complication is often associated with heparine therapy. Rare complications are 
venous outflow and inferior vena cava obstruction (2-4%, respectively). 
Construction of the hepatic vein outflow anastomosis can vary. Most commonly 
in adults, the recipient's retrohepatic part of the inferior vena cava (IVC) is 
removed along with the liver and replaced by the donor's liver with intact IVC. 
Alternatively, frequently in children, the “piggyback” technique is used, 
especially with living related or reduced-size transplantation where it is not 
possible to remove part of the donor's IVC [30, 31]. Using this technique, the 
hepatic vein is anastomosed to the donor's preserved IVC end-to-side while 
creating an enlarged triangular orifice. 
 
Biliary complications (BCs) frequently are sequelae of impaired perfusion and 
ischemia of the graft before or during harvesting as well as during the 
postoperative course. Biliary strictures occur as a consequence of ischemia, 
biliary leaks either are due to ischemia at the anastomosis or due to insufficient 
surgical closure of bile duct structures. BCs are rather common and occur in 5-
30% of children [27] with a varying incidence of 1.6-18% for leaks and 3-23% 
for strictures, occurring more frequently in technically modified transplants. 
Biliary anastomotic strictures present with cholangitis or obstructive jaundice, 
but may also be asymptomatic. Cholangiography and stenting with ERCP 
(endoscopic retrograde cholagiopancreaticography) or PTC (percutaneous 
transhepatic cholangiography) may lead to resolution and avoid the need for 
surgical reconstruction in the majority of cases. If the problem persists, 
conversion to choledochojejunostomy via a Roux-en-Y jejunal limb may be 
required [32]. Non-anastomotic biliary strictures (NAS), also referred to as 
ischemic-type biliary lesions (ITBL), are strictures at any and frequently multiple 
locations in the biliary system other than the anastomosis. They fortunately are 
relatively rare since this type of bile duct stricture is regarded as the most 
troublesome biliary complication. These strictures are often resistant to therapy, 
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frequently associated with long-term sequelae, and one of the more common 
indications for re-transplantation [33]. Biliary leaks can occur at various sites in 
the postoperative period after LT. The majority of postoperative leaks occur at 
the site of anastomosis, but also at the resection surface of the graft in the case 
of LRLT or SLT. Patients present with fever or mild graft dysfunction, and if 
undiagnosed, may progress to biliary peritonitis. HAT or temporary impairment 
of the arterial perfusion is contributing to 25% of all biliary complications and 
should be excluded in all cases.  
 
1.4.2.  Immunosuppressive therapy 
 
The use of immunosuppressive drugs (ISDs) after LT has been essential from 
the early beginnings in order to avoid rejection and risk of transplant function 
impairment.  To reach this goal, a spectrum of ISDs is available. Since the first 
liver transplant, the variety of ISDs has increased and undergone constant 
change, including the development of new drugs. During the early years of 
transplantation, ISDs were limited to anti-metabolic agents, such as 
azathioprine (AZA) and steroids as a global immunosuppressant, often resulting 
in poor outcomes. Corticosteroids have numerous effects on the immune 
system including reduction of circulating T-cells as well as inhibition of leukocyte 
adhesion and inflammatory mediators. The poor side-effect profile of 
corticosteroids is widely recognized and therefore their eventual withdrawal 
after serving as a component of the induction therapy has been widely adopted 
and steroid-free protocols have been introduced.  A standard weaning strategy 
is not universally accepted and some centers do continue low-dose or 
alternating day treatment to minimize undesired effects. A breakthrough in 
rejection control came with the introduction of cyclosporine A (CSA), a 
calcineurin inhibitor (CNI). CNIs activate specific intracellular binding proteins 
(cyclophiline or FK-506) and block the function of calcineurin, which is a 
serine/threonine phosphatase activator. This prevents the production of 
interleukin-2 and thus the activation of T-cells, which are the prime agents of 
rejection [34]. This targeted therapy led to a marked improvement in post-
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transplantation outcome by more than doubling the one year patient survival 
rate [35]. The next advance was achieved by tacrolimus (TAC), a CNI with 
higher potency, allowing steroid withdrawal within the first post-transplant year 
in most patients [36] and excellent control of acute and chronic rejection injury. 
Besides its efficacy [37], the steroid-sparing effect of TAC is of importance to 
preserve the growth potential of children [2]. Another advantage of TAC is the 
lack of cosmetic side-effects associated with CSA which consequently led to a 
switch to TAC in most patients. CNI levels are measured at their trough and the 
dose of CNIs is adjusted based on targeted blood levels. In general, TAC has 
become the predominant CNI and is administered to almost all liver transplant 
recipients (87%) at the time of hospital discharge. CSA is used in a few patients 
who are intolerant of TAC, e.g. due to risk of diabetes mellitus development [38]. 
The acute toxic side effects of CNIs include nephrotoxicity, systemic 
hypertension (HTN), hyperkalemia, hyperlipidemia, neurotoxicity, gastro-
intestinal toxicity and post-transplant diabetes mellitus [27, 34]. Arterial 
hypertension  occurs in 40-80% of liver transplant recipients [39] and often 
needs to be treated with antihypertensive medication such as an ACE inhibitor 
(enalapril) or calcium channel blocker (nifedipine) [40]. In addition to a CNI, the 
current immunosuppressive regimen following LT in children may include the 
purine antagonist mycophenolate mofetil (MMF) which is added in children with 
a history of autoimmune hepatitis, previous immunosuppression (IS) or to 
reduce nephrotoxicity of CNIs. MMF, or rather its active metabolite 
mycophenolic acid (MPA), is a potent and reversible inhibitor of inosine 
monophosphate dehydrogenase (IMPDH), which inhibits the de novo synthesis 
of purines. Since the T- and B-lymphocytes depend on this pathway for their 
proliferation, MPA has a potent cytostatic effect on lymphocytes and can 
therefore be used as an ISD [34]. The most important side effects of MMF are 
gastrointestinal complaints including nausea and diarrhea and hematological 
changes such as leucopenia, anemia and/or thrombocytopenia. Especially in 
children, these side effects sometimes require drug discontinuation. The great 
advantage that MMF has over CNIs is that it does not cause diabetes, HTN, or 
renal toxicity. Several studies have provided evidence that MMF is even 
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effective in reversing structural changes in the kidney [41, 42]. Some studies 
have demonstrated that MMF directly exerts protective effects against 
inflammation and progression of fibrosis [43]. Biologic agents, such as 
basiliximab or daclizumab, are monoclonal antibodies inhibiting the T-cell or one 
of its surface receptors (i.e. IL-2 receptor/ CD 25). Most protocols include these 
anti-IL2 antibodies for induction with or without steroids. Furthermore, their use 
is well accepted due to their favorable renal toxicity profile but because of their 
high cost and requirement of IV administration, they are currently only used for 
induction therapy or rarely for steroid-resistant rejections [44]. Other ISDs that 
may be used after transplantation, however off-label in children, are the mTOR 
inhibitors sirolimus (SIR) or everolimus (EVR). They interact with an intracellular 
pathway inhibiting the mammalian target of rapamycin (mTOR), which impacts 
a variety of relevant metabolic functions in humans. They are used in patients 
with CNI-induced nephrotoxicity because of their renal sparing effect. However, 
there is currently not enough data to precisely describe the risks and potential 
benefits of the drugs but several studies for the pediatric population are 
ongoing. The potential side-effects of mTOR inhibitors may include an 
increased incidence of altered wound healing and dehiscence, hyperlipidemia, 
thrombocytopenia, leucopenia and anemia [45]. 
 
1.4.3.  Rejection and infections  
 
In particular in the early weeks following LT, the balance between adequate 
immune control and the consequences of over-immunosuppression with an 
enhanced risk of infection and other toxic effects remain challenging [46]. In 
clinical practice, it is sometimes difficult to differentiate acute cellular graft 
rejection from other complications since clinical and chemical findings are often 
nonspecific. However, in the majority of children, it is associated with increased 
AST /ALT, bilirubin, alkaline phosphatase and GGT activity, and formally must 
be confirmed with a liver biopsy [22]. The lowest rate of rejection is seen in 
children < 6 months of age and the highest in teenagers who show poor 
compliance with their medications [47]. In stable patients, routine laboratory 
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evaluation should be obtained every 3-4 months to monitor for biochemical 
signs of rejection. Acute rejection is treated with increased doses of CNIs or 3-
day high dose IV corticosteroids, followed by weaning doses of oral steroids 
and adaptation of the IS regimen. Induction therapy with IL-2 receptor 
antibodies can further reduce the rate of acute rejection [48, 49]. In pediatric 
patients, chronic rejection has been a significant cause of graft loss but the 
incidence has decreased from 10% to <5% [47]. Chronic rejection may develop 
after episodes of acute rejection that are not responsive to increased IS and 
often leads to graft loss [22]. It can occur as early as 6 weeks post-transplant 
but is usually most common within the first year or during puberty when the 
incidence of non-compliance increases. The clinical presentation includes 
jaundice and pruritus. Rescue strategies for chronic rejection include adding 
additional immunosuppressants to the existing baseline therapy. Non-response 
to medical management requires re-transplantation. 
 
Infectious complications are important causes of morbidity and mortality 
especially in the first 3 months post-transplant while immunosuppression is at 
its highest. Children with chronic liver diseases considered for LT should 
undergo all available vaccinations before being listed for liver transplantation in 
order to prevent infection related morbidity after surgery in the state of 
immunosuppression. Risk factors for infection include CNI and/ or steroid 
therapy, poor graft function, prolonged intensive care, ventilator dependence, 
gut perforation, re-transplantation, and the use of anti-lymphocyte antibodies to 
treat severe rejection [50]. Bacterial infections are common within the first two 
weeks post-LT. Gram-positive organisms from venous lines remain an important 
cause of sepsis in the first post-operative week, while gram-negative sepsis is 
less common with the use of prophylactic antibiotics during and after surgery. 
As standard medication in the UKT protocol, patients also receive cotrimoxazole 
for PCP prophylaxis. Risk factors for fungal sepsis include graft dysfunction, 
HAT, bile leak, bowel perforation, re-intubation, ALF and previous IS (e.g. 
related to AIH). Most fungal infections are due to candida species but other 
species may also occur. Fungal infections particularly take place in patients with 
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complicated post-LT course and are associated with a high mortality. 
Fluconazole is well tolerated as prophylaxis and therapy, but amphotericin or 
capsofungin are the main stay of treatment. Herpes simplex, varicella zoster, 
CMV, EBV and adenovirus are all potential causes of early and late infections, 
often associated with over-immunosuppression. Young patients, who are more 
likely to be seronegative for these viruses pre-LT, are susceptible to primary 
infections post-LT. Rarely, adenovirus infection causes fulminant hepatitis or 
necrotizing pneumonitis in the early post-LT period with a 45% mortality rate 
[51]. Seventy percent of children develop primary CMV infection post-LT with a 
mortality rate of 7% [52]. CMV, as the most prevalent viral infection, is 
characterized by malaise, fever, leukopenia, thrombocytopenia, arthralgia, and 
later hepatitis, enteritis, or pneumonitis. Other rare late CMV manifestations 
include myocarditis, vasculitis, and encephalomyelitis. Valganciclovir is usually 
given as CMV-prophylaxis for 3 (or 6) months post-transplant depending on 
risks and observed complications. EBV primary infection is defined as systemic 
detection of EBV-DNA load and/or EBV seroconversion in recipients who had 
been EBV-seronegative at the time of transplantation. Associated symptoms 
may or may not be present. EBV reactivation is defined as detectable EBV-DNA 
load in patients already EBV-seropositive at the time of engraftment. EBV 
infection can be categorized as follows: asymptomatic infection, symptomatic 
infection including either flu-like symptoms (fever, malaise, chills) or infectious 
mononucleosis (fever, pharyngitis, lymphadenopathy with or without 
hepatosplenomegaly) and post-transplant lymphoproliferative disease (PTLD) 
[53]. PTLD describes an abnormal proliferation of EBV-infected B-cells which 
occurs in the setting of ineffective T-cell function because of pharmacological 
immunosuppression after organ transplantation. According to different studies, it 
affects 5-15% of children post-LT [54]. It can present in lymphoid tissue in any 
organ, although most commonly in the transplanted organ, lymph nodes, 
gastrointestinal tract, or lungs where it can cause a broad variety of clinical 
symptoms. Most PTLDs are non-Hodgkin lymphomas and nearly all of them are 
associated with EBV infection. Diagnosis is made by the histologic evidence of 
PTLD and EBV association in biopsies of affected organs. Most transplant 
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centers use EBV DNA levels (PCR) to monitor for viral load indicating 
acquisition or reactivation of infection. A high and/or persistent EBV load may 
constitute a valid predictive marker for the later development of EBV-related 
PTLD [55]. The mainstay of treatment is reduction of immunosuppression, but 
this therapeutic option is only based on a high EBV load without clinical 
evidence for PTLD but not on scientific evidence [56]. A promising novel 
therapeutic option to control PTLD is anti-B-cell antibody therapy (rituximab). 
Previously a study showed that valganciclovir post LT was contributing to 
prevention of post LT EBV related complications [57]. 
 
Since long-term maintenance IS increases the risk of infectious and malignant 
complications as well as other side-effects, one of the most important 
management strategies is to find ways of reducing IS toxicity while sustaining 
sufficient immunological protection of the graft. The surgical procedure itself and 
perioperative management remains challenging but has become a routine 
procedure even in small children or patients severely affected, e.g. in acute liver 
failure. However, with significantly improved short-term prognosis, issues 
regarding long-term safety of IS treatment and quality of life come into focus.    
 
 
1.5.  Objectives of this thesis 
 
This thesis aims to answer the following questions: 
 
1. Has the spectrum and frequency of complications following liver 
transplantation in children changed in the current era compared to 
previous periods, specifically: has there been a change in 
frequency and impact of ISD related complications?  
 
2. What are the consequences of the current spectrum of post-
transplant complications for patient management?  
17 
 
2.  METHODS 
 
From February 2005 to October 2011, a total of 52 pediatric patients underwent 
OLT at the University Hospital in Tübingen.  Their data was collected by 
retrospective chart review including medical records, operative reports, 
anaesthesia protocols, ICU medical records, and microbiological and 
pathological reports.  
 
2.1.  Donor and recipient data 
 
The donor parameters include age, sex, and cause of death (COD). 
The recipient parameters include age, sex, ethnicity, diagnosis, and blood 
group. Further data was collected at different time points:   
 
Pre-transplant screening:  
- Weight, height, blood pressure, mean arterial pressure (MAP) 
- Physical exam findings and clinical findings /review of systems (edema, 
cerebral bleeding, cyanosis, hepatomegaly, splenomegaly, skin alterations, 
encephalopathy, jaundice, ascites, fatigue, variceal bleeding, renal failure) 
- Laboratory findings:  
- Electrolytes (sodium, potassium) 
- Osteoporosis parameters (calcium/ phosphate/ PTH), INR 
- Renal function (creatinine, creatinine clearance, cystatin c, urea) 
- Liver function (total/ direct bilirubin, albumin, AST, ALT, GGT, AP)  
- Blood count (thrombocytes, haemoglobin, leukocytes, lymphocytes, 
neutrophils, eosinophils), cholesterol, glucose, pH, bicarbonate, uric acid, 
LDH 
- Auto antibodies (ANA, SMA, LKM): screening for autoimmune hepatitis 
- PCR for EBV, CMV, ADV: pre-transplant viral status  
 
Preoperative admission for transplantation/ Transplant procedure:  
- Physical exam findings, blood pressure, MAP, basic laboratory findings 
- Transplant procedure: MELD (model of end-stage liver disease)/ PELD 
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(pediatric end-stage liver disease), graft type, type of biliary/ vascular 
anastomoses, length of ICU stay, warm ischemia time (WIT), cold ischemia time 
(CIT), immunosuppressive therapy and other medication, histopathology 
  
One, three and six months post-transplant:  
At 1, 3 and 6 months the following data was obtained:   
Physical exam findings, blood pressure, MAP, laboratory findings, auto 
antibodies (ANA, SMA and LKM), PCR (EBV, CMV and ADV), current 
medications, complications and possible therapeutic interventions  
 
Yearly follow-up:  
Each yearly follow-up includes a documentation of the patient's physical exam 
findings, blood pressure, laboratory findings and immunological as well as viral 
diagnostics.  
 
2.2.  Statistical methods 
 
Clinical, biochemical and outcome parameters were entered in a database. 
Using SPSS version 20.0, cohorts with early and delayed referral were 
compared in the univariate analysis using Fisher´s Exact Test for categorical 
and 1-way ANOVA for continuous variables unless mentioned otherwise. 
Correlations were analyzed using the Spearman coefficient with testing two-
tailed significance. Candidate variables at the univariate level were selected for 
multivariate regression if p<0.05. Multivariate logistic regression analysis was 
then used to estimate the relative risk and 95% confidence intervals. 
Differences were considered significant for p-values < 0.05.  
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 3.  RESULTS  
 
3.1.  Study population 
 
3.1.1.  Patient characteristics 
 
The 52 children who underwent liver transplantation between 2005 and 2011 at 
the University Hospital Tübingen (UKT) were included in this retrospective 
single center analysis.  Two patients were excluded from the study because of 
an additional history of stem cell transplantation (ScTx), one of them died in the 
context of transplant failure after ADV infection. The characteristics of the 
remaining 50 children are listed in table 1. 
 
Table 1:     Characteristics of the study population at the UKT 2005-2011 
Characteristics Value 
Total number of transplants 52 
     Excluded (ScTx) 2 
     Included  50 
Follow-up (range of years) 1-7 yr (median: 2 yr) 
Gender 31 boys, 19 girls 
Age at OLT 21 days-19.3 yr (median: 21months) 
Height at OLT 52-179 cm (median: 79.3 cm) 
Weight at OLT 3.6-79 kg (median: 9.9 kg) 
     less than 7 kg 32% (n=16) 
Ethnicity Europe: 82% (n=41) 
  Near/ Middle East: 14% (n=7) 
  Far East: 4% (n=2) 
Blood group A: 48% (n=24) 
  0: 40% (n=20) 
  B: 10% (n=5) 
  AB: 2% (n=1) 
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3.1.2.  Indications for liver transplantation 
 
 
Primary indications for LT at our centre include both cholestatic disorders, e.g. 
biliary atresia, metabolic disorders, e.g. Wilson’s disease, conditions leading to 
cirrhosis, e.g. autoimmune hepatitis, acute liver failure and tumors such as 
hepatoblastomas. For further details see table 2. 
 
 
Table 2:     Indications for liver transplantation at the UKT 2005-2011 
Diagnosis Value % 
Biliary atresia (BA) 26 52 
Acute liver failure (ALF) 5 10 
Alagille syndrome 3 6 
Progressive familial intrahepatic cholestasis (PFIC) 2 4 
Hepatoblastoma 2 4 
Autoimmune hepatitis (AIH) 2 4 
Idiopathic cirrhosis 2 4 
Gestational alloimmune liver disease (GALD) 2 4 
Non-cirrhotic portal hypertension 2 4 
Caroli-syndrome 1 2 
Crigler-Najjar syndrome 1 2 
Wilson's disease (WD) 1 2 
Liver cirrhosis 1 2 
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3.1.3.  Transplant procedure 
 
Mean PELD score at transplant was 15.5 (range of PELD 0-41, median: 16.0), 
valid for all children less than 12 years. Mean MELD score at transplant was 
14.3 (range of MELD 10-25, median: 14.0), valid for all children older than 12 
years, relevant for organ allocation in the North-American UNOS system. The 
time spent on the ICU ranged from 3 to 75 days (median: 6 d). Cold ischemia 
time (CIT) ranged from 30min - 19h 22min (median: 6.5 h), CIT is declining for 
the more recent transplantations. CIT in LDLT ranged from 30min - 3h 35min 
(mean: 63.5min), CIT in SLT ranged from 2h 3min - 16h 27min (mean: 10h 
28min), and CIT in full-size LT ranged from 3h 26min - 19h 22min (mean: 9h 
3min). Warm ischemia time (WIT) was between 17- 70 min (median: 38 min). 
 
Different surgical transplant techniques were used for transplantation (see 
figure 1). Sixty-four percent (n=32) of liver grafts were from deceased donors 
(DD), including full-size grafts and split grafts from which segments 2-3 (left-
lateral lobe) were transplanted in 11 patients (22%) and segments 1, 4-8 (right 
lobe) in 7 patients (14%). Liver transplantation from living donors (LD) was 
performed with the left-lateral lobe in 30% (n=15) and the left lobe (segments 2-
4) in 3 patients (6%). 
 
 
 
 
28% 
36% 
36% 
DD, full-size graft
DD, split graft
LD, left (-lateral)
Figure 1:  Graft types at the UKT from 2005-2011; LD: living donor, 
DD: deceased donor 
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The hepatic artery anastomosis was mostly performed end-to-end (86%, n=43) 
whereas the portal vein anastomosis was end-to-end in all patients (98%, 
documentation in 1 case inconclusive). To anastomose the hepatic vein, the so 
called “piggy-back” technique was used in 52% (n=26), in 42% (n=21) of 
patients the inferior vena cava was replaced by donor cava and in the rest of 
the patients the method was not specified. The biliary anastomosis was either 
end-to-end (choledocho-choledochostomy) in 16 patients (32%) or in the form 
of a biliodigestive anastomosis (BDA) in 58% (n=29) of patients.  
 
3.1.4.  Donor data 
 
The donor age including all post-mortem and living donors ranged from 0-55 
years (median: 25 years), including 35 female and 15 male donors. Their CMV 
IgG Status was positive in 25 donors, negative in 23 donors and unknown in 
two donors (see table 3).  
 
Table 3:     Donor data from deceased and living donors at the UKT 2005-2011 
Characteristic DD (n=32) LD (n=18) 
Age, years 0-55 (median: 17) 19-50 (median: 33) 
Sex, male/female 13/19 2/16 
CMV status, pos/neg 18/13 (1 unknown) 7/10 (1 unknown) 
Body weight, kg 4-95 (median: 55 )   
 
 
The deceased donors include 14 full size transplants and 18 split transplants.  
COD in DD was: 3 anoxia, 1 cerebrovascular accident, 5 cerebral edema, 2 
intracranial bleeding, 3 meningitis, 8 subarachnoidal hemorrhage, 6 traumatic 
brain injury, 1 suicide, 2 trauma, 1 unknown. The living donors include 14 
mothers, 1 father, 1 step father, 1 adoptive mother, 1 grandmother. 
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3.2.  Patient and graft survival in different transplant periods 
 
In a literature review, articles describing pLT in different time periods were 
reviewed and the respective patient and graft survival data are listed in table 4. 
The data was compared to the results at the UKT from 2005-2011 where both 
patient and graft survival rates were 100%. No patient with isolated LT died or 
had to receive a re-transplant. 
 
Table 4:     Patient and graft survival from 1985 to 2010 
Period Studies 5 yr patient survival 5 yr graft survival 
1985-1990 Otte et al. [18] 73,6% 80,5% 
  Esquivel et al. [58] 69,2% 73,0% 
  Lloyd-Still et al. [59] 64,0%   
1990-1995 Drews et al. [60] 78,0% 68,0% 
  Busuttil et al. [23] 77,0% 75,0% 
  Yamanaka et al. [61] 75,0% 63,0% 
1995-2000 Miller et al. [62] 80,9% 78,0% 
  Deshpande et al. [63] 88,1% 86,1% 
  Bourdeaux et al. [64] 88,5% 83,0% 
2000-2005 Wallot et al. [65] 91,4% 87,3% 
  Gridelli et al. [66] 91,0% 80,0% 
  Oliveros et al. [67] 96,0% 89,0% 
2005-2010 UKT 100,0% 100,0% 
 
 
The data shows a constant improvement in both patient and graft survival over 
the past 25 years. The respective mean patient and graft survival for every 5 
year period is depicted in figure 2.  
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3.3.  Vascular and biliary complications 
 
3.3.1.  Results at the UKT from 2005-2011 
 
A total of 136 complications were analyzed. In the following, the categories of 
complications will be discussed divided up by vascular complications, biliary 
complications, rejection and infections as well as complications associated with 
calcineurin inhibitor immunosuppression. 
 
Vascular complications (VCs) at the UKT from 2005-2011 were found in a total 
of 9 patients (18%). See table 5. 
 
The following vascular complications at the UKT required interventional 
treatment: The HAT was treated by relaparotomy and surgical revision. The PVT 
(affection of segments 2 and 3 only) which led to portal HTN required treatment 
in the form of a thrombectomy. The venous stenoses were treated by balloon 
angioplastic dilatation. 
68,9 
76,7 
85,8 
92,8 
100 
76,7 
68,7 
82,4 85,4 
100 
0
20
40
60
80
100
120
85-90 90-95 95-00 00-05 UKT 05-10
5yr pt survival 5yr graft survival
Figure 2:  Patient and graft survival from 1985-2010  
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Table 5:     Vascular complications at the UKT from 2005-2011 
Complication 
 
Value % 
Thrombosis Hepatic artery thrombosis (HAT) 1 2 
  Portal vein thrombosis (PVT) 1 2 
Stenosis Hepatic artery stenosis 1 2 
  Portal vein stenosis 2 4 
  Inferior vena cava stenosis 2 4 
  Hepatic vein stenosis 2 4 
 
 
Relaparotomy 
A total of 15 patients (30%) required a relaparotomy due to the following 
causes: post-operative bleeding occurred in 10 patients (20%), abscesses in 2 
patients, suspected or actual hypoperfusion in 2 patients and HAT in 1 patient.  
At the UKT, a direct abdominal closure could be performed in all but one case in 
which closure was performed as a two-step procedure. 
 
 
Biliary complications (BCs) at the UKT from 2005-2011 occurred in 36% of the 
patients (n=18). See table 6. 
 
Table 6:     Biliary complications at the UKT from 2005-2011 
Complication Value % 
Biliary anastomotic strictures 14 28 
Biliary leaks 2 4 
Ischemic type biliary lesions (ITBL) 2 4 
 
The BCs at the UKT mostly required surgical intervention due to recurrent 
episodes of cholangitis. The interventional treatment included surgical revision 
with a new BDA in 10 patients presenting with biliary strictures and biliary leaks. 
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Three patients required ERCP: in the first patient balloon angioplasty was 
performed, the second received a stent placement and in the third, flushing due 
to sludge was done. As a change in management, percutaneous transhepatic 
cholangio-drainage (PTCD) was increasingly used as a therapeutic option in 6 
cases, requiring re-intervention in 2 cases, leading to resolving stricture and 
stable biliary drainage in 4 cases. 
 
In terms of BCs, it is common to differentiate between early complications and 
late complications. This differentiation was also used for the complications seen 
at the UKT from 2005-2011 resulting in the following: 
Early complications (occurring during the initial post-transplant hospitalization) 
were observed in 7 patients (3 biliary strictures, 2 ITBL, 2 biliary leaks).  
Late complications (occurring after patients have been discharged home) were 
observed in 11patients (11 biliary strictures). 
 
3.3.2.  Potential predictors of biliary complications 
 
The data of the 50 patients was analyzed for potential predictors of biliary 
stenoses after pediatric liver transplantation. Figures 3-5 show that pre-
transplant parameters have a significant influence on the occurrence of biliary 
stenoses including alkaline phosphatase, bilirubin and sodium. Patients with 
lower pre-transplant levels of alkaline phosphatase (p < 0.005), direct bilirubin 
(p < 0.038), and sodium (p < 0.012) seem to experience biliary stenoses more 
frequently. This indicates a potential relevance of recipient-specific laboratory 
parameters on the frequency of biliary complications. 
 
In our study group no significant differences in the number of biliary stenosis 
were found for CIT, WIT, PELD, MELD, donor age, weight of the recipient. 
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      Figure 3:  Pre-transplant alkaline phosphatase 
 
Figure 4:  Pre-transplant direct bilirubin 
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The influence of the pre-transplant sodium was also shown to be significantly 
associated with the number of biliary stenosis in a stepwise multivariate 
analysis (p < 0.007). In this analysis, sodium was the only independent 
parameter that was associated with the occurrence of biliary stenoses. 
 
 
3.3.3.  Vascular and biliary complications in different transplant periods 
 
To compare the number of VCs and BCs from this study with different transplant 
eras, a literature review of data from different time periods was done. 
Comparing the results, a notable decrease in the number of VCs can be found 
from 1985 until the present day whereas the number of BCs increased over the 
years. See table 7 and figure 6. 
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Figure 5:  Pre-transplant sodium 
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Table 7:     Vascular and biliary complications from 1985-2010   
Period Studies VC total VC Studies BC total BC 
1985-1990 Wozney et al. [68] 68,0% Bhatnagar et al. [69] 10,0% 
  Lerut et al. [70] 10,0% Letourneau et al. [71] 38,0% 
  Lallier et al. [72] 21,0% Lallier et al. [73] 25,0% 
1990-1995 Bell et al. [74] 16,0% Patkowski et al. [75] 18,7% 
  Yamanaka et al. [61] 15,0% Egawa et al. [76] 16,3% 
  Bilik et al. [25] 25,0% Heffron et al. [77] 13,6% 
1995-2000 Mali et al. [78] 19,7% Miller et al. [62] 18,0% 
  Eid et al. [79] 14,0% Gridelli et al. [66] 27,0% 
  Sieders et al. [80] 21,0% Bourdeaux et al. [64] 26,0% 
2000-2005 Broniszczak et al. [81] 16,8% Oliveros et al. [67] 29,9% 
  Shirouzu et al. [82] 15,4% Anderson et al. [83]  26,0% 
  Yilmaz et al. [84] 24,7% Kling et al. [85] 33,0% 
2005-2010 UKT 18,0% UKT 36,0% 
 
Figure 6 displays the data from table 7 in a graph: 
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Figure 6:  Vascular and biliary complications from 1985-2010 
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To specify the different BCs reported in the studies, the number of biliary leaks 
from 1985-2005 ranged from 4%-20% vs. 4% at the UKT from 2005-2010. The 
number of biliary strictures is reported to range from 5-34% [86] vs. 36% at the 
UKT.  
 
The VCs in the era from 1985-2005 are further differentiated in the studies as 
well: HAT ranged from 4.9-42% vs. 2 % at the UKT from 2005-2010, PVT and 
portal vein stenosis ranged from 1.5-16.7% vs. 6% at the UKT, hepatic artery 
stenosis ranged from 1.2-11% vs. 2 % at the UKT, hepatic vein stenosis and 
thrombosis ranged from 1.2-6% vs. 4% at the UKT and IVC stenosis and 
thrombosis ranged from 1-3% vs. 4% at the UKT.  
 
3.4.  Rejection and infections 
 
To compare the number of rejections and infections, a separate literature review 
was done for both number of rejections and infections in different transplant 
eras of the past. Table 8 and figure 7 display the significant decline in the 
number of rejections over the past years. The number of rejections in the UKT 
program includes acute rejection in 3 patients (6%) and chronic rejection in 1 
patient (2%) which was due to non-compliance. 
 
Table 8:     Number of rejections after pLT from 1990-2010 
Period Studies Rejection 
1990-1995 Drews et al. [60] 68,0% 
  Dunn et al. [87] 57,0% 
1995-2000 Shepherd et al. [88] 46,0% 
  Martin et al. [89] 60,3% 
2000-2005 Sanada et al. [90] 46,6% 
  Indolfi et al. [91] 32,3% 
2005-2010 UKT 8,0% 
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The frequency of LT associated infections has also changed in 2005-2010 
compared to previous periods. The result of the literature review is displayed in 
table 9 and graph 8 including the total number of patients with post-transplant 
infections, the number of bacterial infections as well as CMV and EBV 
(including primary infections and clinically relevant re-activations). 
 
Table 9:     Number of infections after pLT from 1985-2010 
Period  Total Bacterial CMV EBV 
1985-1995  54,0% [92] 62,0% [60]  33,0% [60] 63,0% [93] 
   72,0% [94] 68,0% [94] 41,0% [95] 31,4% [96]  
1995-2005  52,0% [88] 51,9% [97] 19,8% [98] 50,6% [99] 
   60,0% [100]   18,0% [91] 56,0% [101] 
05-10 UKT  46,0% 16,0% 12,0% 34,0% 
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Figure 7:  Number of rejections from 1990-2010  
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Infectious complications are less frequent now compared to past periods. 
Especially bacterial infections are significantly less common than previously 
reported. The bacterial infections seen at the UKT in 2005-2010 include mostly 
pneumonia (including two cases with pneumocystis carinii) and sepsis.  
 
With regard to viral infections, the results of this study show a decrease in the 
total number of CMV and EBV infections. CMV infection today was seen in less 
than half of the patients compared to data from 1985-2005. Hence, the 
prophylactic regimen of valganciclovir for 3 (or 6) months post-transplant may 
be effective in reducing the number of CMV complications. A correlation to the 
Donor CMV-status could be observed: out of the 6 patients in this study cohort 
who developed a clinically relevant CMV infection, 5 donors were CMV positive. 
Out of these 5 patients, 4 had been CMV negative before LT. EBV primary 
infection (positive PCR) occurred in 17 patients (34%). The spectrum of EBV-
related morbidity ranged from asymptomatic and symptomatic infections to 
EBV-associated PTLD which occurred in 2 patients (4%). Both PTLDs were 
treated with a reduced immunosuppressive regimen and rituximab (anti CD 20). 
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Figure 8:  Infections after pLT in 1985-2005 compared to UKT 2005-2010 
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To summarize, the spectrum of complications with regard to the surgical 
procedure and infectious causes has changed. The number of biliary 
complications has increased whereas the number of infections and vascular 
problems has decreased. Some complications (e.g. primaray non-function) 
were not observed at all in analysis of the recent cohort. 
 
3.5.  Complications associated with CNI immunosuppression 
 
A differentiation of post pLT complications does not allow a strict division 
between the events occurring in the operative and post-operative phase both 
related to the surgical procedure and multidisciplinary acute peri- and post-
operative management. However, a separate analysis of CNI-related morbidity 
is important due to the fact that these complications alone require significant 
efforts in management resources. These complications are summarized in  
table 10. 
Table 10:     CNI-associated complications at the UKT from 2005-2011 
Complication n % 
Hypertension 32 64 
Renal insufficiency 14 28 
Hyperkalemia 5 10 
Hematological alterations 5 10 
GI symptoms 5 10 
Neuropsychiatric disorders 3 6 
Diabetes / impaired glucose tolerance  3 6 
Failure to thrive 2 4 
Chronic oral mucosal lesion 2 4 
Food allergy 1 2 
Celiac disease 1 2 
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Arterial HTN and renal insufficiency both play a major role in the post-transplant 
care today since they are common and require antihypertensive medications. 
Hyperkalemia as well as acidosis are likely associated with renal insufficiency.  
The observed hematological complications show a spectrum of disorders 
including: 2 patients with anemia, 1 pancytopenia, 1 autoimmune hemolytic 
anemia (AIHA), 1 myelosuppression. GI-symptoms include both diarrhea and 
recurrent episodes of vomiting in 3 patients each, one being affected by both 
symptoms. Neuropsychiatric complications included both seizures in 2 patients 
and 1 patient with psychosis. Causality with CNI is likely due to synchronicity of 
CNI treatment and neurologic symptoms, the lack of further identifiable other 
etiology and the control of symptoms following modifications of CNI treatment. 
Diabetes/ impaired glucose tolerance (IGT) is also known as a common side-
effect of this immunosuppression and seen in 3 CNI-treated patients. Failure to 
thrive, oral mucosal lesions (OMLs), food allergy and new-onset celiac disease 
are non-classifiable complications that may be associated with pre-existing 
conditions or ISDs. 
 
3.6.  Dominance of CNI-associated complications 
 
Table 10 shows that 73 (54%) out of a total of 136 complications occurred as 
direct side-effects of calcineurin inhibitor immunosuppression. This dominance 
of CNI-associated side-effects over surgical and infectious complications 
expresses a change of paradigm in the spectrum of complications following pLT.  
If infectious complications and rejections, which in a broader sense are also 
related to CNIs, are also included in the group of CNI-associated complications, 
the dominance is even more evident with 94 (69%) out of 136 total 
complications. This shift towards CNI-associated complications is also depicted 
in figure 9 (non-CNI- associated complications include vascular and biliary 
complications and complications that required a relaparotomy).  
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3.7.  CNI therapy and alternatives  
 
The immunosuppressive regimens that were administered at the UKT in the 
immediate post-OP period after LT, as well as 1, 3, 6 months and one year later 
are shown in table 11. The IS regimens more than one year after LT are not 
listed because of a small number of follow- up patients.  
 
Table 11:     Immunosuppressive regimen at the UKT until 1 year after pLT 
  CNI MMF mTOR inhibitor 
perioperative 
100% 
49 TAC, 2 CSA 
14% 
(n=7) 
- 
1 month 
98% 
 48 TAC, 2 CSA 
28% 
(n=14) 
- 
3 months 
98% 
47 TAC, 2 CSA 
28% 
(n=14) 
- 
6 months 
97% 
42 TAC, 4 CSA 
23% 
(n=11) 
4% 
(n=2) 
1 year 
86% 
34 TAC, 4 CSA 
27%  
(n12) 
11% 
(n=5) 
31%  
(n=42) 
69% 
(n=94) 
Non-CNI-ass.
complications
CNI-associated
complications
Figure 9:  Dominance of CNI-associated complications  
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To decrease CNI-associated side effects two strategies were applied: firstly, the 
reduction of CNI levels and addition of a further IS (e.g. MMF) and secondly, 
once intolerable side-effects were identified, a CNI-free regimen was 
established. One option to replace CNIs is the use of mTOR-inhibitors such as 
everolimus or sirolimus. Out of the 50 patients in our study population, 13 (26%) 
received a secondary modification of their immunosuppressive medications to a 
CNI-free regimen (see table 12). The switch to CNI-free immunosuppression 
was done 5 months to 10 years following LT. 
 
Table 12:     Change to CNI-free immunosuppression to reverse adverse effects 
Adverse effects No. CNI-free regimen Outcome 
Nephrotoxicity,  
Hyperkalemia 
2 EVR/ MMF 2 resolved 
  2 EVR 
1 converted to LD steroids/  
MMF, 1 resolved 
  1 EVR/ LD steroids resolved 
severe food allergy,  
eczema 
1 EVR improved 
AIHA 1 EVR/ LD steroids 
elevated transaminases,  
azathioprine added 
Pancytopenia 1 SIR improved 
Chronic OMLs 2 1 MMF, 1 SIR 1 improved 
Persistent high  
EBV load 
1 EVR/ MMF resolved 
PTLD 1 MMF / LD steroids rejection, cyclosporine added 
 
As indicated in table 12, there were various adverse effects (e.g. renal or 
haematological problems) that made the switch from a CNI-based therapy to a 
CNI-free regimen necessary. The CNI-related adverse events were resolved in 
9 of the 13 patients and the new IS regimen was tolerated well. Side effects of 
secondary non-CNI treatment are listed in table 13. 
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Table 13:     Complications of CNI-free regimen and their management 
Complication Action taken  Number 
Rejection (biopsy proven) cyclosporine introduction 1 
Transiently elevated  
transaminases  
adaptation of EVR levels in 1 
case, azathioprine in 1 case 
2 
Edema of lower extremities,  
proteinuria 
switch EVR – SIR 2 
Relaparotomy indicated replacement of mTOR-inhibitors 1 
 
 
The effect of changing IS-regimen to CNI-free immunosuppression is shown in 
the improvement of the GFR both pre and post conversion in 4 patients:  
 
 
 
 
 
0
20
40
60
80
100
120
140
160
Pre-conversion 4-6 mo post conversion
G
F
R
 i
n
 m
l/
m
in
 
Pt 1
Pt 2
Pt 3
Pt 4
Figure 10:  GFR improvement in 4 patients pre- and post-conversion;  
GFR: glomerular filtration rate 
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4.  DISCUSSION  
 
This is the first retrospective study comparing the spectrum of complications of 
a single pLT program to data published in previous periods. The primary 
objective was to analyze whether there was a change in the type and frequency 
of complications after pLT, with emphasis on the relation of CNI-related 
complications versus complications related to the surgical procedure, and to 
discuss the consequences of the current spectrum of post-transplant 
complications for patient management. We were able to show that, associated 
with improvement in patient and graft survival, the spectrum of complications 
after pLT has changed significantly during the periods studied. Compared to 
previous studies, a significant shift from complications related to the surgical 
transplantation procedure towards CNI-associated complications was observed 
in our study cohort. This dominance of CNI-associated complications points to a 
need to reconsider the strategies in current post LT management.  
 
Several contributors to this change in the spectrum of complications can be 
identified. Underreporting in previous (early) studies may play a role. Even 
though hypertension and nephrotoxicity, the most prevalent side effects of CNIs, 
were also described in earlier transplant periods [102, 103], they were not the 
primary focus. Two decades ago, the focus in pediatric liver transplantation was 
on improvement of the surgical procedure, e.g. through expanding the donor 
pool by introduction of living-donation or the splitting procedure, while improving 
survival of both patients and grafts with a limited spectrum of ISDs. Therefore, 
in this context, CNI-associated undesired effects had potentially been less in 
focus compared to other risks of high impact such as transplant failure and 
severe infections which were responsible for many deaths in the previous 
periods of pLT. In comparison, in our study no deaths from serious bacterial, 
fungal, or viral infections were reported. The high incidence in earlier studies 
may be associated with more severe degrees of liver disease at the time point 
of presentation and less experience in the operative and perioperative 
management. Compared to previous periods the broadened experience in use 
of technically modified and living donation grafts in patients at risk may have 
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also had a positive influence on patient and graft survival. In addition, the 
availability of novel antiviral drugs has changed post-operative treatment. CMV 
or EBV naïve infants who receive CMV or EBV positive grafts are particularly 
vulnerable to infections with these viruses. The use of the CMV antiviral 
prophylaxis valganciclovir has reduced CMV-associated risk even though 
studies continue to report CMV disease rates as high as 10-14% [104, 105] 
which is similar to our study.  
 
In this study, we reviewed the outcome of 50 primary liver graft recipients in a 1-
7 year follow-up period. Survival rates for this selected group were excellent, 
being 100% for both grafts and patients with isolated liver grafts. This compares 
favorably with recently published data from the European liver transplant 
registry that showed 1-year patient survival rates of 85% and graft survival rates 
of 75% [106]. These single center results may indicate that liver transplantation 
has reached the threshold of a new era where survival of the patient is 
considered the likely outcome and attention will now be focused more on long-
term patient and graft survival. Different studies have been published which also 
describe a patient survival rate of 100% but lack a similar high graft survival 
rate. Broering et al. [107] reports a series of 132 consecutive pediatric liver 
transplants with an actual 6-months patient survival rate of 100%. Three 
children died after hospital discharge (98% actual patient survival rate). The 
high patient survival rate was not sustained by a high graft survival: 3-month 
and actual graft survival rates were 92% and 86%, respectively, leading to a 
total number of 16 re-transplants (12%). The three main reasons for graft loss 
were PNF (n=5), arterial thrombosis (n=4) and chronic rejection (n=5). 
Borenstein et al [108] published patient and graft survival rates of 100% after 13 
living donor liver transplants in children. The limitation of this study is the very 
small size of the study cohort. Between 1993 and 2002, the group from 
Brussels performed 235 primary liver transplants with a 5-year recipient survival 
rate of 85% in the cadaveric group (n=135) and 92% in the LRLT group (n=100) 
[109]. The group from Kings College in London published an actual 6-month 
patient survival rate of 96.2% after 80 consecutive pediatric liver transplants 
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[63]. The different authors identified factors that contributed to their good 
outcomes. Broering et al. recognized that the year of transplantation turned out 
to be the strongest significant factor in predicting patient survival, underlining 
the learning curve in their center. Further contributing factors included careful 
selection of good quality grafts, adequate choice and performance of the 
splitting technique, the technique of graft implantation and standardized post-
transplant care, including close follow-up of the hepatic flow [107]. 
 
Compared to previous reports on pLT we were able to show a constant decline 
in the total number of surgical complications, especially in the number of 
vascular problems. However, biliary complications remain a major source of 
morbidity after LT, leading to repeated interventions and adaptations of 
therapeutic regimens. The reasons may be the frequent use of technically 
modified grafts and vulnerability to ischemia-reperfusion damage. 
Manifestations of bile duct damage are seen at the anastomotic region or at 
multiple locations of the donor biliary system (ITBL). As shown in the literature 
review, the incidence of BCs did not vary much since the first LT, with an overall 
reported incidence still between 10 and 35% [110]. Potential contributors to a 
persistent number of BCs are discussed by various authors. Verdonk et al. 
observed an increase of biliary anastomotic strictures after 1995 [32], possibly 
related to an increased use of organs with extended donor criteria. According to 
Seehofer et al. major risk factors include old donor age, partial liver grafts and 
prolonged ischemia time. These risk factors could be partially confirmed in our 
analysis regarding cold ischemia time and old donor age. Even though our 
center did not confirm partial liver grafts as a significant risk factor, technically 
modified grafts are frequently discussed with regard to the increase in BCs. 
Darius et al. [110] also hypothesized that the use of alternative techniques 
(reduced-size, split and living donation) in pLT contributed to an increase in the 
incidence of BCs. However, they came to the conclusion that graft type was not 
found as an independent risk factor for the development of BCs. According to 
their analysis only HAT and acute rejection were significant risk factors for 
anastomotic BCs. An analysis of the SPLIT database demonstrates a 24-month 
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BC rate of 17% for whole organ recipients, 28% for split recipients, 25% for 
reduced size, and 40% for live donor [111]. While the use of living donor and 
technical variants of deceased donor grafts does increase the BC rate 
according to studies from the SPLIT database, it is important to remember that 
these technically modified grafts contributed to significantly reducing the 
shortage of size-matched organs for children on the LT waiting list. Even though 
the different authors agree that BCs following pLT remain an important and 
challenging problem, many factors that increase the risk for BCs like donor age 
or steatosis may be difficult to address with regard to the shortage of suitable 
donors. However, it is generally accepted that the best prerequisite for low 
biliary morbidity is adequate perfusion with active bleeding at the biliary ends, 
preservation of periductal tissue and avoidance of vascular injury to the bile 
duct vessels, e.g. by extensive cautery [112]. Concepts on how to manage 
biliary complications vary. The majority of centers use ERC plus balloon 
dilatation with [113] or without [114] stent placement for the treatment of 
anastomotic strictures in patients with preserved biliary anatomy. Since about 
75% of pediatric LT are performed with a bilioenteric anastomosis [111], most 
biliary complications in this patient group are managed by percutaneous 
intervention +/- stent placement. Darius et al., despite its more invasive nature, 
prefer primary surgical intervention which in their experience provides better 
results in terms of quality of life than repeated radiological interventions.  
 
Due to improvement of post-LT survival data, CNI-associated adverse effects 
and complications have moved into focus as the treatment post LT is aiming at 
undisturbed development and minimizing therapy associated morbidity. The 
impact of CNI-related side-effects is variable: they may be serious and result in 
mortality, e.g. through PTLD, their impact may be moderate but significantly 
impair quality of life, e.g. food allergies, or they may frequently affect 
extrahepatic organ function, e.g. renal dysfunction and arterial hypertension.  
Hypertension and nephrotoxicity as the most prevalent side effects of CNIs are 
associated with significant morbidity and mortality in both children and adults 
[115-117]. In pediatric LT recipients, it has been shown that hypertension is 
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predictive of long-term renal insufficiency [118]. This result corresponds with our 
findings at the UKT since all children developing renal insufficiency have a 
history of preceding hypertension except for one. As such, a repeatedly 
elevated blood pressure or decreased GFR requires treatment to prevent long-
term consequences. In fact, treating patients for hypertension even if they do 
not meet the conventional criteria (>95th percentile) for treatment is an approach 
used by a growing number of centers to prevent renal comorbidities [119-123] 
since patients who develop post-LT chronic renal failure due to CNIs have a 
more than four-fold higher mortality than those who do not [124, 125]. A recent 
longitudinal study by Anastaze Stelle et al. of 24 pediatric liver transplant 
recipients on TAC also analyzed renal function and hypertension [126]. They 
found that the lower the TAC level, the better the renal function (Creatinine 
Clearance, CrCl). This indicates that the CNI-dose plays an important role 
which at the same time implies an approach to prevent renal damage. The dose 
dependency was also confirmed in other studies which showed that long-term 
low-dose CNI therapy was not associated with deterioration of renal function in 
children [127, 128]. Further investigations examined the number of patients 
requiring antihypertensive therapy: at three months post-OLT, 65.2% of patients 
needed antihypertensive therapy while only 33% were receiving 
antihypertensives 36 months post-OLT [126]. Among these patients the ones 
with a combined therapy including nifedipine and enalapril had better renal 
function than patients on one drug alone, although the observed effect on CrCl 
did not reach statistical significance [40]. The mechanism of TAC-related 
hypertension is still incompletely elucidated, but it appears that TAC creates an 
imbalance of vasoconstrictors and vasodilators contributing to renal and 
systemic vasoconstriction [129-132]. In general, there is an acute and a chronic 
CNI-induced nephropathy. The acute form of CNI toxicity may be reversed when 
CNI administration is reduced or withdrawn. In contrast, the chronic form of 
CNI-induced nephrotoxicity is characterized not only by renal vasoconstriction 
but also by the development of structural damage, including arteriolopathy and 
tubulointerstitial fibrosis, which are irreversible and need to be avoided due to 
the potential to cause end-stage renal disease [133]. To conclude, identifying 
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and treating hypertension early on may prevent long term morbidity and 
improve prognosis and quality of life since more than 90% of patients receive an 
immunosuppressive regimen based on CNIs after LT [134].  
 
At our center 100% of patients received a CNI (48 TAC only, 1 CSA only, 1 TAC 
and CSA consecutively) in the period following LT. After 1, 3 and 6 months, 98% 
of the IS was CNI based. One year after LT, only 86% still received a CNI based 
therapy whereas the rest of the patients were switched to a CNI-free regimen 
due to CNI-related adverse effects. Hence, immunosuppressive strategies are 
needed to reduce the incidence of CNI-associated complications. There are 
different options as well as new approaches in order to reduce the number of 
CNI-related side-effects: One strategy is the individual minimization and 
weaning off IS. Present research efforts are focusing on approaches aiming at 
operational tolerance (OT) which is defined as stable graft function for 1 year 
without IS. There have been several published reports of the successful 
weaning of 11-38% of liver transplant recipients from IS [135]. A study at the 
Kyoto University Hospital reported that 88 of 581 pediatric living donor liver 
recipients (15%) were operationally tolerant [136, 137]. Feng et al. [138] 
performed a pilot study including 20 highly selected pediatric recipients of 
parental living donor liver transplants who were discontinued from their 
immunosuppressive therapy by a stepwise reduction over a minimum of 36 
weeks. As a result, 60% of the patients (n=12) remained off IS for at least 1 year 
with both normal graft function and stable allograft histology and were termed 
“operationally tolerant”. Many of the 12 operationally tolerant children 
experienced serious adverse events after weaning such as biliary obstruction, 
cholangitis or portal vein stenosis. The 8 “non-tolerant” patients had to be 
treated with an increased or a re-initiation of immunosuppression therapy 
mostly due to acute or indeterminate rejection. Severe or steroid refractory 
acute rejection, chronic rejection, graft loss, or deaths were not observed. The 
challenge now is to find markers for operational tolerance and thus wean 
patients from CNI using these markers as guidance and safety parameters in 
the process. Waki et al. [139] studied the role of anti-human leukocyte antigen 
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(HLA) antibodies after pediatric living-donor liver transplantation, trying to 
investigate whether the presence of HLA antibodies impeded the development 
of OT. They concluded that post-transplantation HLA antibodies were 
associated with the inability to reach OT. A prospective study with more patients 
is necessary to confirm the predictive value of HLA antibodies for OT. Another 
novel approach of tolerance induction is the use of mesenchymal stem cells 
(MSCs). MSCs inhibit the immune response in vitro, and thus are promising 
candidate cells to promote acceptance of transplanted organs in vivo. Popp et 
al. [140] demonstrated that donor-derived MSCs induce long-term allograft 
acceptance in a rat heart transplantation model when concurrently treated with 
a short course of low-dose MMF. They concluded that MSCs constitute a 
promising tool for the induction of graft tolerance but further investigation in 
clinical trials is needed. Considering the results from the above mentioned 
studies, CNI minimization in the form of complete withdrawal may be an option 
to limit or to improve CNI toxicity,   provided that CNI exposure has not already 
caused irreversible damage. However, the balance between efficacy and the 
risk of rejection needs to be carefully weighed [141-145].  
 
A second strategy is the use of alternative ISDs with improved toxicity profiles.  
After a reduction or even withdrawal of CNI some months after LT, adequate 
immunosuppression can be maintained by adding MMF or mTOR inhibitors 
[145-149]. It has been shown that regimen change led to improved kidney 
function without resulting in a higher rejection rate. However, not all patients 
seem to profit from this strategy, possibly because irreversible kidney damage 
has already taken place [150]. Few studies have evaluated the long-term use of 
MMF in liver transplanted children with renal dysfunction. Aw et al. [151] studied 
the efficacy of MMF as renal rescue in 14 pediatric liver transplant recipients 
with CNI-related nephrotoxicity. Side effects of MMF included acute rejection in 
three children, leukopenia in two and backache in one. They found that MMF 
allowed the recovery of renal function from CNI-related nephrotoxicity in more 
than 70% of pediatric liver transplant recipients with renal impairment. Tannuri 
et al. [152] evaluated 191 liver transplanted children out of which 11 patients 
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developed renal dysfunction secondary to prolonged use of CSA or TAC. All of 
these were switched to a MMF immunosuppressant protocol with reduced 
doses of CNIs. As a result, 82% showed improvement of renal function 
parameters in comparison with the pretreatment values. No episodes of acute 
or chronic rejection or increases in infection rates during the period were 
detected. Evans et al. [153] report that in 92% of children with renal dysfunction 
after LT, MMF treatment provided safe and effective immunosuppression and 
allowed CSA or TAC to be discontinued or reduced, leading to improved renal 
function.  At our center, 6 patients were switched to MMF due to CNI-related 
side-effects. All of them improved under MMF except for one. 
The number of studies investigating mTOR inhibitor-based immunosuppression 
using either sirolimus (SIR) or everolimus (EVR) in children is still limited. The 
few published prospective randomized-controlled studies are limited by small 
patient cohorts and short follow-up periods [154-156]. Hocker et al. [157] 
compared SIR-based immunosuppression and CNI minimization in pediatric 
renal transplant recipients with chronic CNI nephrotoxicity. They concluded that 
in pediatric transplant recipients with declining kidney function due to CNI-
induced nephrotoxicity, a switch to SIR-based therapy or CNI minimization were 
associated with a comparable improvement of GFR after 12 months of 
observation. The main adverse event under SIR therapy was transient 
hyperlipidemia in 70% of patients. No patient in either group experienced an 
acute rejection episode. Gibelli et al. reported on their experience with SIR in 
pediatric liver transplant recipients at a single-center. Out of 318 liver 
transplanted children, 13 were converted to SIR therapy because of TAC-
related side effects. The indications were PTLD in 11 patients, nephrotoxicity 
and de novo AIH in one patient each. After conversion, no episodes of acute 
rejection were observed, PTLD recurred in one patient and one child developed 
hyperlipidemia. They concluded that conversion from TAC to SIR in selected 
pediatric liver transplant recipients was safe and especially children with PTLD 
may benefit from IS with SIR after LT. In our study, 11 patients were switched to 
an mTOR-inhibitor based regimen due to CNI-associated side-effects with an 
overall positive result and few mTOR-related side-effects. 
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A third strategy to reduce IS toxicity is the combination of CNI with adjunctive 
drugs. One example is the combination of CNIs and hydrochlorothiazide with a 
possible protective effect on both hypertension and renal function. Hoorn et al. 
[158] confirmed the hypothesis that CNIs induce hypertension by stimulating the 
renal sodium chloride co-transporter (NCC). They showed that TAC did not 
affect blood pressure in NCC-knockout mice, whereas the hypertensive 
response to TAC was exaggerated in mice overexpressing NCC. Therefore, 
they suggested reversing TAC-induced hypertension by adding an NCC-
blocking drug like hydrochlorothiazide. The use of these inexpensive and well-
tolerated thiazide diuretics was also started in the most recent patients of the 
study group at the UKT with the attempt to prevent the complications of CNI 
treatment. So far, this approach may prove to be effective in treating CNI-
induced hypertension and hyperkalemia, but exact results need to be further 
evaluated. A different experimental approach in a rat model is described by 
Hoskova et al. [159] who discovered that TAC-induced hypertension and 
nephrotoxicity were attenuated by dual inhibition of the renin-angiotensin 
system (RAS). Their experiments led to the result that TAC-induced arterial 
hypertension in rats was prevented by dual RAS inhibition, using perindopril and 
losartan, as well as by a combination of amlodipine and metoprolol. However, 
significant nephroprotection (reduced albuminuria) was only observed in 
animals on dual RAS inhibition. In addition, histological analysis revealed that 
RAS inhibition noticeably diminished glomerulosclerosis and tubulo-interstitial 
injury which further supports the notion that RAS inhibitors display efficient 
renoprotective properties during CNI treatment.  
 
Further research is needed to develop immunosuppressive strategies with 
improved toxicity profiles. Recent progress in the development of biologicals, 
i.e. antibodies and fusion proteins, allow precise targeting of the immune 
system, preventing the non-immune side effects encountered with current 
protocols. In particular, targeting of the two most important co-stimulation 
pathways critical for T-cell activation, i.e. B7/CD28 and CD40/CD40L, has 
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provided excellent results in many experimental models of organ 
transplantation. This has led to the clinical development of belatacept, a 
cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin (CTLA4-Ig) fusion 
protein, which has proved to be efficient in preventing acute rejection in kidney 
transplant recipients [160]. Its use is associated with improved renal function 
and a better metabolic profile than CNIs. However, a trial analyzing efficacy in 
liver transplanted patients had to be stopped due to an increased prevalence of 
intracranial bleeding.  
 
In summary, the establishment of novel operative techniques, the development 
of more effective immunosuppressants, an improved overall patient 
management and timing of transplantation as well as the decrease in the 
number of infections and the introduction of CMV prophylaxis and other 
additional medication may have contributed to a significantly improved patient 
and graft survival with a consecutive shift in focus on quality of life issues and 
adverse effects of the immunosuppressive therapy. 
 
4.1.  Limitations and benefits of this study 
 
Our study has several limitations. Due to the retrospective nature of the study, a 
limited number of patient values are missing.  Furthermore, a follow-up range 
from 1-7 years with a median of only 2 years is insufficient to completely 
estimate the long-term implications of CNI exposure on kidney function and 
other long-term side-effects. Lastly, the results of our single center study group, 
limited by its number of patients (50), cannot be easily transferred to other 
patient groups. 
 
This study does, however, contribute to the increasing number of publications 
highlighting the changes in management of pLT in the last periods and the 
challenges in the administration of CNIs. It focuses on the discussion of relevant 
consequences for patient management and long term outcomes. One important 
contribution of this study is to demonstrate a change in the spectrum of post-
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pLT complications in comparison with previous reports. Another important 
contribution is to highlight different approaches of CNI-free immunosuppression 
avoiding CNI- associated toxicity and thus allowing adequate and undisturbed 
child development and improved quality of life. 
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5.  SUMMARY 
 
Until recently, the postoperative course of pLT was complicated most frequently 
by surgical complications such as arterial or portal vein thrombosis and severe 
infections, leading to both graft and patient loss. The objective of this study is to 
demonstrate a significant shift in pLT-related complications to a dominance of 
CNI-associated side effects. Therefore, a retrospective chart review of 50 
children (31 boys, 19 girls) was performed who underwent pLT between 2005 
and 2011. Most common indications were biliary atresia in 52% and acute liver 
failure in 10%. Age at pLT ranged from 21 days-19years (median: 21 months), 
body weight was 3.6-79 kg (median 9.9 kg). Immunosuppressive regimen was 
based on tacrolimus (TAC) and tapered prednisolone. Full-size post-mortem 
grafts were transplanted in 28%, split grafts (left-lateral, left lobe or right lobe) 
and living- donation grafts in 36% each. Range of PELD was 0-41 (median: 16). 
Patient and graft survival rates improved over the last decades having reached 
100% at the UKT from 2005-2011. The number of VCs with currently 18% 
(including HAT in only 1 patient) as well as the rate of rejections and infections 
decreased over the last years. BCs remain a constant problem occurring in 18 
patients (36%), of which 28% were biliary anastomotic strictures. A literature 
review was done to show the development in the spectrum and number of 
complications in previous periods of pLT. In our study, 94 (69%) out of 136 
complications were associated with CNI-treatment of which hypertension (64%) 
and nephrotoxicity (28%) were most prevalent. Other CNI-related side-effects 
included hematological or neuropsychiatric disorders, GI-symptoms, diabetes, 
food allergy or failure to thrive which at times required a discontinuation from 
CNIs and the introduction of alternative therapeutic regimens. This indicates 
that future management of patients after pLT needs to increasingly focus on 
strategies to reduce CNI-toxicity including the individual minimization and 
weaning, the use of alternative ISDs with beneficial toxicity profiles (MMF, 
mTOR inhibitors) or the combination of CNI with adjunctive drugs (e.g. HCTZ) 
to ensure adequate development and improved quality of life.  
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6.  ZUSAMMENFASSUNG 
 
Der postoperative Verlauf nach LT im Kindesalter wurde bis vor kurzem 
vorwiegend durch chirurgische Komplikationen wie z.B. Thrombosen oder 
Infektionen bestimmt, die zu Patienten- und Transplantatverlust führten. Ziel 
dieser Studie ist es eine signifikante Veränderung der post-LT Komplikationen 
mit zunehmender Dominanz CNI-assoziierter Nebenwirkungen aufzuzeigen. 
Dazu wurden die Daten der 50 Kinder (31 Jungen, 19 Mädchen), die von 2005 
bis 2011 eine LT am UKT erhielten, retrospektiv analysiert. Die häufigsten 
Indikationen waren GA in 52% und ALV in 10%. Das Alter bei LT reichte von 21 
Tagen bis 19 Jahren (Median: 21 Monate), das Körpergewicht lag zwischen 3,6-
79 kg. Die Immunsuppression bestand aus Tacrolimus und Prednisolon. Ganze 
Organe von post mortem Spendern wurden in 28% transplantiert, Teil-
Transplantate bzw. Lebendspenden in jeweils 36%. Sowohl Patienten- als auch 
Transplantatüberleben haben sich in den letzten Jahrzehnten deutlich 
verbessert mit aktuell jeweils 100% im Zeitraum von 2005-2011 am UKT. Dies 
wurde erreicht durch einen Rückgang in der Anzahl von Gefäßkomplikationen 
(18%) sowie Infektionen und Abstoßungsreaktionen. Komplikationen der 
Gallenwege bleiben ein anhaltendes Problem in 36% der Patienten. In einer 
Literaturrecherche wurden das Spektrum und die Anzahl an Komplikationen 
nach LT in der Vergangenheit analysiert. Von den beobachteten 136 
Komplikationen waren 94 (69%) mit der CNI-Therapie assoziiert, wobei 
Bluthochdruck (64%) und Nierenschädigung (28%) am häufigsten waren. Als 
weitere CNI-assoziierte Komplikationen wurden z.B. neuropsychiatrische oder 
hämatologische Störungen, Diabetes oder Nahrungsmittelallergien beobachtet. 
Daher wurde z.T. eine Umstellung der Immunsuppression auf eine CNI-freie 
Therapie nötig. Diese Ergebnisse zeigen, dass die Patientenbehandlung nach 
LT künftig das Ziel haben muss CNI-Komplikationen zu verhindern. Möglich 
wäre z.B. der Gebrauch alternativer Immunsuppressiva wie mTOR-Inhibitoren 
oder die Ergänzung der CNI-Therapie durch andere Medikamente (z.B.HCTZ). 
Nur so kann eine adäquate Entwicklung und Lebensqualität von LT-Patienten 
gewährleistet werden.   
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